Drug Patents owned by Progenics Pharms Inc

1. List of Pylarify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487129 PROGENICS PHARMS INC Heterodimers of glutamic acid
Nov, 2027

(4 years from now)

US9861713 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Jul, 2029

(6 years from now)

US8778305 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Sep, 2030

(7 years from now)

US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in